{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:17:32Z","timestamp":1792473452181,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":2745,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/ki.2008.35","type":"journal-article","created":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T16:02:24Z","timestamp":1203523344000},"page":"1355-1363","source":"Crossref","is-referenced-by-count":70,"title":["Vitamin D receptor activation and survival in chronic kidney disease"],"prefix":"10.1016","volume":"73","author":[{"given":"C.P.","family":"Kovesdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2008.35_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0015","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0025","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/ki.1982.70","article-title":"Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency","volume":"21","author":"Portale","year":"1982","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.ki.5000045","article-title":"Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation","volume":"69","author":"Andress","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncpendmet0394","article-title":"Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"3","author":"Brown","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1038\/ki.2008.35_bb0045","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJM198706183162504","article-title":"Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure","volume":"316","author":"Korkor","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2008.35_bb0050","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ki.1997.41","article-title":"Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism","volume":"51","author":"Gogusev","year":"1997","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0055","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0272-6386(97)90086-X","article-title":"Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure","volume":"30","author":"Kates","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0060","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1172\/JCI113946","article-title":"Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat","volume":"83","author":"Yamamoto","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2008.35_bb0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/jcem-41-2-339","article-title":"Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism","volume":"41","author":"Llach","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2008.35_bb0070","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00467-006-0230-3","article-title":"FGF23: its role in renal bone disease","volume":"21","author":"Fukagawa","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2008.35_bb0075","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1744-9987.2005.00291.x","article-title":"Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism","volume":"9","author":"Kazama","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1038\/ki.2008.35_bb0080","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0272-6386(97)90009-3","article-title":"Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure","volume":"29","author":"Chertow","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0090","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0095","series-title":"Kidney Int","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","author":"Goodman","year":"2007"},{"key":"10.1038\/ki.2008.35_bb0100","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), CaxPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.jrn.2006.07.006","article-title":"Impact of kidney bone disease and its management on survival of patients on dialysis","volume":"17","author":"Lee","year":"2007","journal-title":"J Ren Nutr"},{"key":"10.1038\/ki.2008.35_bb0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","article-title":"Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population","volume":"19","author":"Shoji","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.35_bb0120","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0125","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0130","series-title":"Arch Intern Med","article-title":"Association of treatment with activated vitamin D and mortality in chronic kidney disease","author":"Kovesdy","year":"2008"},{"key":"10.1038\/ki.2008.35_bb0135","first-page":"219","article-title":"Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia","volume":"14","author":"Massry","year":"1994","journal-title":"Semin Nephrol"},{"key":"10.1038\/ki.2008.35_bb0140","first-page":"335","article-title":"Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus","volume":"8","author":"Mazzaferro","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.35_bb0145","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/meta.2000.17708","article-title":"Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level","volume":"49","author":"Chiu","year":"2000","journal-title":"Metabolism"},{"key":"10.1038\/ki.2008.35_bb0150","first-page":"29","article-title":"Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients","volume":"17","author":"Gadallah","year":"2001","journal-title":"Adv Perit Dial"},{"key":"10.1038\/ki.2008.35_bb0155","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0026-0495(97)90212-2","article-title":"Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality","volume":"46","author":"Wareham","year":"1997","journal-title":"Metabolism"},{"key":"10.1038\/ki.2008.35_bb0160","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1172\/JCI110154","article-title":"Effect of parathyroid hormone on erythropoiesis","volume":"67","author":"Meytes","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2008.35_bb0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJM199301213280304","article-title":"Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia","volume":"328","author":"Rao","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2008.35_bb0170","first-page":"186","article-title":"Secondary hyperparathyroidism and the immune system in chronic renal failure","volume":"11","author":"Massry","year":"1991","journal-title":"Semin Nephrol"},{"key":"10.1038\/ki.2008.35_bb0175","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0180","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/01.CIR.96.6.1755","article-title":"Active serum vitamin D levels are inversely correlated with coronary calcification","volume":"96","author":"Watson","year":"1997","journal-title":"Circulation"},{"key":"10.1038\/ki.2008.35_bb0185","doi-asserted-by":"crossref","first-page":"c21","DOI":"10.1159\/000088295","article-title":"Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis","volume":"102","author":"Kim","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2008.35_bb0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2008.35_bb0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s004410051353","article-title":"Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3","volume":"297","author":"Bellows","year":"1999","journal-title":"Cell Tissue Res"},{"key":"10.1038\/ki.2008.35_bb0200","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/excr.2002.5474","article-title":"1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2\/Cbfa1 gene promoter","volume":"274","author":"Drissi","year":"2002","journal-title":"Exp Cell Res"},{"key":"10.1038\/ki.2008.35_bb0205","first-page":"1237","article-title":"Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines","volume":"44","author":"Virdi","year":"1998","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"key":"10.1038\/ki.2008.35_bb0210","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0021-9258(19)35439-0","article-title":"1,25-Dihydroxyvitamin D3 stimulates the synthesis of matrix gamma-carboxyglutamic acid protein by osteosarcoma cells. Mutually exclusive expression of vitamin K-dependent bone proteins by clonal osteoblastic cell lines","volume":"263","author":"Fraser","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2008.35_bb0215","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1046\/j.1523-1755.1998.00152.x","article-title":"Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium","volume":"54","author":"Panichi","year":"1998","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0220","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.4049\/jimmunol.168.3.1181","article-title":"1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells","volume":"168","author":"Staeva-Vieira","year":"2002","journal-title":"J Immunol"},{"key":"10.1038\/ki.2008.35_bb0225","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.20011629","article-title":"In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines","volume":"195","author":"Barrat","year":"2002","journal-title":"J Exp Med"},{"key":"10.1038\/ki.2008.35_bb0230","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.4049\/jimmunol.167.9.4974","article-title":"1Alpha,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells","volume":"167","author":"Boonstra","year":"2001","journal-title":"J Immunol"},{"key":"10.1038\/ki.2008.35_bb0235","doi-asserted-by":"crossref","first-page":"35798","DOI":"10.1074\/jbc.M404865200","article-title":"Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice","volume":"279","author":"Aihara","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2008.35_bb0240","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response","volume":"311","author":"Liu","year":"2006","journal-title":"Science"},{"key":"10.1038\/ki.2008.35_bb0245","first-page":"D820","article-title":"Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis","volume":"6","author":"Hansen","year":"2001","journal-title":"Front Biosci"},{"key":"10.1038\/ki.2008.35_bb0250","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2008.35_bb0255","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2008.35_bb0260","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.298.10.1163","article-title":"Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial","volume":"298","author":"Jamison","year":"2007","journal-title":"JAMA"},{"key":"10.1038\/ki.2008.35_bb0265","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1038\/ki.2008.35_bb0270","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/ije\/31.5.1030","article-title":"An overview of relations among causal modelling methods","volume":"31","author":"Greenland","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1038\/ki.2008.35_bb0275","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/ije\/31.2.422","article-title":"Estimating causal effects","volume":"31","author":"Maldonado","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1038\/ki.2008.35_bb0280","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1038\/ki.2008.35_bb0285","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jama.297.3.278","article-title":"Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods","volume":"297","author":"Stukel","year":"2007","journal-title":"JAMA"},{"key":"10.1038\/ki.2008.35_bb0290","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0295","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/ndt\/gfm286","article-title":"High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients","volume":"22","author":"Voormolen","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.35_bb0300","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1681\/ASN.2005101101","article-title":"Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease","volume":"17","author":"Norris","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0305","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.02101205","article-title":"Association of disorders in mineral metabolism with progression of chronic kidney disease","volume":"1","author":"Schwarz","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0310","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1523-1755.2002.kid573.x","article-title":"Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats","volume":"62","author":"Slatopolsky","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0315","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","article-title":"Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone","volume":"10","author":"Finch","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0320","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0325","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1359\/jbmr.2002.17.5.879","article-title":"Vitamin D analogue-specific recruitment of vitamin D receptor coactivators","volume":"17","author":"Issa","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2008.35_bb0330","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2005.06.046","article-title":"Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells","volume":"186","author":"Wu-Wong","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1038\/ki.2008.35_bb0335","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.ki.5002458","article-title":"Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol","volume":"72","author":"Repo","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0340","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1046\/j.1523-1755.63.s85.20.x","article-title":"New vitamin D analogs","volume":"63","author":"Slatopolsky","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0345","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.070305","article-title":"Differential effects of vitamin D analogs on vascular calcification","volume":"22","author":"Cardus","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2008.35_bb0350","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0355","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2008.35_bb0360","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.35_bb0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00044011-200727020-00003","article-title":"Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan","volume":"27","author":"Gal-Moscovici","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1038\/ki.2008.35_bb0370","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2165\/00044011-200626110-00002","article-title":"Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis","volume":"26","author":"Rosery","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1038\/ki.2008.35_bb0375","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.me.43.020192.001303","article-title":"The use of 1,25-dihydroxyvitamin D3 in early renal failure","volume":"43","author":"Goodman","year":"1992","journal-title":"Annu Rev Med"},{"key":"10.1038\/ki.2008.35_bb0380","first-page":"98","article-title":"Renal function during calcitriol therapy in chronic renal failure","volume":"33","author":"Bertoli","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2008.35_bb0385","first-page":"1520","article-title":"No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure","volume":"9","author":"Coen","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.35_bb0390","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0395","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0400","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","article-title":"Antiproteinuric effect of oral paricalcitol in chronic kidney disease","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0405","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1681\/ASN.2006050520","article-title":"Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy","volume":"17","author":"Tan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0410","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison","volume":"37","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0415","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0420","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0425","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0430","first-page":"315","article-title":"A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease","volume":"56","author":"Lindberg","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2008.35_bb0435","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0440","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.106.101261","article-title":"Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification","volume":"318","author":"Wu-Wong","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/ki.2008.35_bb0445","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2008.35_bb0450","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP65335","article-title":"Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients","volume":"65","author":"Joist","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2008.35_bb0455","first-page":"S62","article-title":"Risk of adynamic bone disease in dialyzed patients","volume":"38","author":"Malluche","year":"1992","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2008.35_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"Bone metabolism and disease in chronic kidney disease","volume":"42","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0465","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1020146023812","article-title":"Interleukin-6 induced suppression of bovine parathyroid hormone secretion","volume":"19","author":"Carlstedt","year":"1999","journal-title":"Biosci Rep"},{"key":"10.1038\/ki.2008.35_bb0470","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1006\/bbrc.1997.7207","article-title":"Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an upregulation of the calcium-sensing receptor mRNA","volume":"238","author":"Nielsen","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/ki.2008.35_bb0475","first-page":"198","article-title":"Serum albumin levels, an additional factor implicated in hyperparathyroidism outcome in peritoneal dialysis: a prospective study with paired bone biopsies","volume":"22","author":"Sanchez-Gonzalez","year":"2006","journal-title":"Adv Perit Dial"},{"key":"10.1038\/ki.2008.35_bb0480","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem-67-5-876","article-title":"Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure","volume":"67","author":"Pitts","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2008.35_bb0485","doi-asserted-by":"crossref","first-page":"c132","DOI":"10.1159\/000098645","article-title":"Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients","volume":"105","author":"Saab","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2008.35_bb0490","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.ki.5000394","article-title":"25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells","volume":"70","author":"Ritter","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0495","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease","volume":"27","author":"Zisman","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2008.35_bb0500","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/0003-4819-88-6-774","article-title":"1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study","volume":"88","author":"Berl","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2008.35_bb0505","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/archinte.167.16.1730","article-title":"Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials","volume":"167","author":"Autier","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2008.35_bb0510","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.bjp.0702581","article-title":"Recovery of impaired K+ channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol","volume":"127","author":"Borges","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1038\/ki.2008.35_bb0515","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.34.4.897","article-title":"Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine","volume":"34","author":"Borges","year":"1999","journal-title":"Hypertension"},{"key":"10.1038\/ki.2008.35_bb0520","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0090-6980(91)90072-N","article-title":"Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells","volume":"42","author":"Wakasugi","year":"1991","journal-title":"Prostaglandins"},{"key":"10.1038\/ki.2008.35_bb0525","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1681\/ASN.2006060573","article-title":"Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency","volume":"18","author":"London","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.35_bb0530","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(78)90184-5","article-title":"The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy","volume":"64","author":"Bordier","year":"1978","journal-title":"Am J Med"},{"key":"10.1038\/ki.2008.35_bb0535","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/ncpneph0443","article-title":"Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol","volume":"3","author":"Hernandez","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1038\/ki.2008.35_bb0540","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.35_bb0545","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2008.35_bb0550","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.35_bb0555","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ceca.2003.10.016","article-title":"Calcium-sensing receptor regulation of renal mineral ion transport","volume":"35","author":"Ba","year":"2004","journal-title":"Cell Calcium"},{"key":"10.1038\/ki.2008.35_bb0560","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","article-title":"Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview","volume":"2","author":"Chertow","year":"2007","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815529402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815529402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T12:40:21Z","timestamp":1630759221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815529402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":111,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0085253815529402"],"URL":"https:\/\/doi.org\/10.1038\/ki.2008.35","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}